enGene (NASDAQ:ENGN) Trading Down 5.4%

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report)'s stock price fell 5.4% during mid-day trading on Tuesday . The company traded as low as $14.50 and last traded at $14.65. 309,038 shares changed hands during mid-day trading, an increase of 421% from the average session volume of 59,352 shares. The stock had previously closed at $15.49.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ENGN shares. Leerink Partnrs reaffirmed an "outperform" rating on shares of enGene in a research report on Tuesday, February 20th. Guggenheim initiated coverage on shares of enGene in a report on Monday, April 15th. They issued a "buy" rating and a $34.00 price target for the company. SVB Leerink initiated coverage on shares of enGene in a report on Tuesday, February 20th. They set an "outperform" rating and a $31.00 price objective on the stock. Morgan Stanley started coverage on shares of enGene in a research note on Friday, March 8th. They issued an "overweight" rating and a $40.00 target price for the company. Finally, Wells Fargo & Company started coverage on enGene in a research note on Monday, April 22nd. They issued an "overweight" rating and a $30.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $34.40.

enGene Price Performance

The firm's fifty day moving average price is $16.21.

Insider Buying and Selling at enGene

In other news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the company's stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the sale, the insider now owns 3,036,153 shares in the company, valued at approximately $45,542,295. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 13.70% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vivo Capital LLC bought a new position in shares of enGene during the 4th quarter worth approximately $6,264,000. BVF Inc. IL acquired a new stake in enGene during the 4th quarter valued at $20,777,000. Omega Fund Management LLC bought a new position in enGene during the fourth quarter worth $10,441,000. Finally, Fcpm Iii Services B.V. acquired a new position in shares of enGene in the fourth quarter valued at $80,097,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.